fbpx

Dr Ray Asghari

MD, FRACP
Medical Oncologist
Refer a patient

Dr Ray Asghari is dedicated to achieving the best possible outcome for his patients. He prides himself in building strong, lasting relationships with his patients throughout their cancer journey.

Biography

Dr Ray Asghari is an experienced medical oncologist at Icon Cancer Centre Revesby. He graduated with a Doctor of Medicine at the University of Tehran and completed his specialist oncology training at Sydney’s Liverpool, Royal Prince Alfred and Concord Hospitals. Dr Asghari is a fellow of the Royal Australasian College of Physicians and Staff Specialist at Bankstown-Lidcombe Hospital since 2007.

Dr Asghari is actively involved in medical leadership, research and clinical trials in both his private practice and role as Director of Cancer Services & Head of Department of Medical Oncology at Bankstown-Lidcombe Hospital. He is an active member of several leading cancer trial groups including Australian Gastro-Intestinal Trials Group (AGITG), Australian Pancreatic Cancer Genome Initiative (APGI) and Australia and New Zealand Breast Cancer Trials Group (ANZBCTG). Dr Asghari has been active in several clinical trials and acted as Principal Investigator in major cooperative and pharmaceutical studies investigating prostate, gastrointestinal and lung cancers.

Dr Asghari’s clinical experience covers a broad range of solid tumour malignancies, with special clinical interests in gastrointestinal, lung, breast and genitourinary cancers.

Affiliations & Memberships

  • Australian Medical Association (AMA)
  • The Royal Australasian College of Physicians (RACP)
  • Medical Oncology Group of Australia (MOGA)
  • Clinical Oncology Society of Australia (COSA)
  • American Society of Clinical Oncology (ASCO)
  • European Society of Medical Oncology (ESMO)
  • Australian Gastro-Intestinal Trials Group (AGITG)
  • Australian Pancreatic Cancer Genome Initiative (APGI)
  • Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)
  • European Association of Cancer Research (EACR)

Special Interests

Dr Asghari accepts referrals for all cancer types, with a special clinical interest in:
  • Breast cancer
  • Gastrointestinal cancer
  • Genitourinary cancer
  • Lung cancer

Icon Locations

Revesby View centre

Publications

  • Chemotherapy in Rectal Cancer: Variation in utilisation and development of an evidence-based benchmark rate of optimal chemotehrapy utilisation. Susannah Jacob, Weng Ng, Ray Asghari, Geoff P. Delaney, Michael B. Barton. Clinical Colorectal Cancer, 2011; 10 (2): 102-107.

  • Lorraine Chantrill, Amber Johns, Adnan Nagrial, Venessa Chin, Angela Chou, Mark Pinese, Scott Mead, Val Gebski, Katrin Sjoquist, Chee Lee, Sonia Yip, Danielle Miller, Lucille Sebastian, Ray Asghari, Sandra Harvey, Nick Pavlakis, Sanjay Mukhedkar, Peter Grimison, David Miller, John Pearson, Nicola Waddell, Sean Grimmond, John Simes, Andrew Biankin. The IMPaCT trial: Individualised Molecular Pancreatic Cancer Therapy. A pilot, randomized, open label Phase II trial assessing first line treatment with gemcitabine or personalized treatment based on tumour molecular signature in patients with metastatic pancreatic cancer. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, 2013; 12(11 Suppl): A75.

  • Health-related quality of life during chemoradiation in locally advanced rectal cancer: impacts and ethnic disparities. Stephanie Hui-Su Lim, Emilia Ip, Weng Ng, Wei Chua, Ray Asghari, Aflah Roohullah, Joseph Descallar, Christopher Henderson, Kevin Spring, Paul de Souza, Madeleine T. King. Cancers, 2019; 11 (9).

  • Predictive and prognostic biomarkers for neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Stephanie Hui-Su Lim, Wei Chua, Christopher Henderson, Weng Ng, Lorraine Chantrill, Ray Asghari, Cheok Soon Lee, Kevin Spring, Paul de Souza. Critical Reviews in Oncology/Haematology, 2015; 96 (1): 67-80.

  • Precision medicine for advanced pancreas cancer: early lessons learned from negotiating the pitfalls of a molecular therapeutics trial in a poor prognosis cancer. Lorraine Chantrill, Amber Johns, Clare Watson, Scott Mead, Anthony J. Gill, Nick Pavlakis, P. Grimison, Ray Asghari, B. Li, Adel Choi, S. Simpson, Mona Martyn-Smith, Adnan Nagrial, Venessa Chin, Lucielle Sebastian, S. Yip, K. Sjoquist, Sean Grimmond, R.J. Simes, Andrew Biankin. Annals of Oncology, 2014; 25 (4).

View all doctors

Search